Change over period: —
NSE · BROOKS
BROOKS LABS
-39.0% from the 52-week high · +80.4% above the low
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The firm has manufacturing plants at Baddi, Himachal Pradesh. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
The short version. BROOKS LABS reported revenue of ₹19 crore for Sep 2026, down 17.4% from a year earlier. Net profit was ₹68 crore (up 750.0% year on year). Return on equity was 20.0% in Mar 2026. Promoter holding was 52.62% in Sep 2026, down 6.44 points over 8 quarters.
1 · The price
How has the stock traded?
BROOKS LABS trades 39.0% below its 52-week high and 80.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹19 cr.
Sep 2026 net profit of ₹68 cr.
317.3 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 23 | 20 | 17 | 23 | 26 | 23 | 21 |
| Net profit | 68 | -2 | 1 | 5 | 8 | 10 | -1 | -2 |
| Net margin % | 351.3 | -7.8 | 7.4 | 33.2 | 34.0 | 37.6 | -6.3 | -10.4 |
| EPS (₹) | 22.95 | -0.61 | 0.51 | 1.87 | 2.71 | 3.25 | -0.49 | -0.81 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 86 | 83 | 79 | 63 | 91 | 77 |
| Net profit | 25 | -10 | -20 | -21 | -16 | -19 |
| Net margin % | 28.6 | -12.1 | -24.6 | -33.1 | -17.8 | -25.1 |
| EPS (₹) | 8.34 | -3.38 | -7.46 | -7.96 | -6.17 | -7.38 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 20.0% in Mar 2026; debt to equity is 0.06.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 20.0 | -10.2 | -29.9 | -28.3 |
| Return on capital % | 5.3 | 4.2 | 3.6 | -43.9 |
| EBITDA margin % | 9.5 | 7.0 | 5.2 | -41.9 |
| Net margin % | 28.2 | -11.9 | -24.4 | -33.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 11.1% | 2.2% |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 6.44 pts over 8 quarters.
Up 0.03 pts over 8 quarters.
Up 6.64 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.06 | 52.62 | 52.62 | 52.62 | 52.62 | 52.62 | 52.62 | 52.62 | -6.44 |
| FII | 0.01 | 0.05 | 0 | 0.01 | 0.09 | 0.17 | 0 | 0.04 | +0.03 |
| DII | 3.86 | 10.38 | 10.38 | 10.38 | 10.38 | 10.38 | 10.38 | 10.5 | +6.64 |
| Public | 37.08 | 36.95 | 37.0 | 37.0 | 36.91 | 36.84 | 37.0 | 36.84 | -0.24 |
Mutual fund holdings · Oct 2026
1 scheme hold this stock
1 the month before.
- quant Business Cycle Fund1.98% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for BROOKS LABS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about BROOKS LABS
What is the BROOKS LABS share price?
BROOKS LABS (BROOKS) last closed at ₹67.30, up 0.51% on the day. Its 52-week range is ₹37.11 to ₹109.82.
What is the market cap of BROOKS LABS?
BROOKS LABS has a market capitalisation of about ₹197 crore. Its price-to-earnings ratio is 3.0.
How are BROOKS LABS's latest results?
BROOKS LABS reported revenue of ₹19 crore for Sep 2026, down 17.4% from a year earlier. Net profit was ₹68 crore (up 750.0% year on year). Return on equity was 20.0% in Mar 2026. Promoter holding was 52.62% in Sep 2026, down 6.44 points over 8 quarters.
Who owns BROOKS LABS?
As of Sep 2026, shareholding was: Promoter 52.62%, FII 0.04%, DII 10.5%, Public 36.84%.
How many mutual funds hold BROOKS LABS?
1 mutual fund schemes held BROOKS LABS in October 2026. That compares with 1 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 28 Jul 2023 · Rights issue 1:16
- 11 Feb 2020 · Rights issue 9:20
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.